{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037198","form_type":"8-K","ticker":null,"cik":"0001082038","company_name":"DURECT CORP","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.311499+00:00","generated_at":"2026-06-04T06:57:20.184837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DURECT reports Q4/FY2023 results; larsucosterol shows mortality reduction in Phase 2b AH trial","bullets":["Q4 2023 total revenues $2.7M, net loss $1.4M vs $3.3M and $10.5M in Q4 2022.","Full year 2023 revenues $8.5M, net loss $27.6M vs $19.3M and $35.3M in 2022; cash $29.8M.","Larsucosterol 30mg reduced 90-day mortality 41% (p=0.068); 90mg reduced 35% (p=0.124).","In U.S. patients, mortality reductions of 57% (30mg, p=0.014) and 58% (90mg, p=0.008).","Entered co-marketing agreement with Charles River for ALZET osmotic pumps in U.S./Canada."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037198","json":"https://secwatch.observer/filing/0000950170-24-037198.json","markdown":"https://secwatch.observer/filing/0000950170-24-037198.md","text":"https://secwatch.observer/filing/0000950170-24-037198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/0000950170-24-037198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/drrx-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:57:20.184837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f0e74e60c2a70d3eb2bb5c7c05382b35e2097e0","claim":"DURECT CORP reported fourth quarter and full year 2023 results: revenue $2.7 million, net income net loss was $1.4 million.","evidence_excerpt":"Total revenues were $2.7 million and net loss was $1.4 million for the three months ended December 31, 2023 compared to total revenues of $3.3 million and net loss of $10.5 million for the three months ended December 31, 2022. Total revenues were $8.5 million and net loss was $27.6 million for the year ended December 31, 2023, compared to total revenues of $19.3 million and net loss of $35.3 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/0000950170-24-037198-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Revenue","value":"$2.7 million"},{"label":"Net income","value":"net loss was $1.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}